Legend Biotech (LEGN) prices offering of 7.7 mln ADSs at $29.35 per ADS

• Legend Biotech prices 7.7 million ADS underwritten offering at $29.35 each for expected gross proceeds of approximately $226 million
•  Legend Biotech (NASDAQ: LEGN) went public on June 5, 2020, raising approximately $424 million in its initial public offering (IPO). The company originally offered 18.4 million American Depositary Shares (ADS) at a price of $23.00 per share.
• https://legendbiotech.com/

Porch Group (PRCH) reported earnings on 6 May 25 (a/h)

• The Seattle-based home services technology company Porch Group went public on December 24, 2020, following a merger with the special purpose acquisition company (SPAC) PropTech Acquisition Corp., and a private investment from Wellington Management Company.
• Its shares began trading on the Nasdaq under the ticker symbol PRCH.

Porch CEO and founder Matt Ehrlichman

Porch Group went public on December 24, 2020

Relay Therapeutics (RLAY) reported Q3 earnings on Thur 6 Nov 25 (a/h)

Relay Therapeutics is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease.

• It reported third quarter 2025 financial results today, including a net loss of $74.1 million, and announced the appointment of Lonnel Coats and Habib Dable to its Board of Directors.

** charts before earnings **

 

** after earnings **

Arcutis Biotherapeutics (ARQT) reported earnings on Tue 28 Oct 25 (b/o)

• Arcutis Biotherapeutics reports Q3 2025 results with $99.2M in ZORYVE sales, $7.4M net income, issues 2026 revenue guidance, and outlines growth strategy at Investor Day presentation.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. 

The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. 

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 342
• Incorporated in 2016 
• Headquartered in Westlake Village, California.
• https://www.arcutis.com

IPO: Jan 31, 2020

Ticker: ARQT

 

 

 

 

Arcutis Biotherapeutics announces third quarter 2025 results; provides initial 2026 full year net product sales guidance of $455-$470 mln

WESTLAKE VILLAGE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today outlined its strategy to achieve sustainable growth and reported financial results for the quarter ended September 30, 2025.

Kymera Therapeutics (KYMR) : atopic dermatitis potential matches Sanofi/Regeneron's blockbuster Dupixent in early biomarker response

Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine.

The findings significantly surpassed the company’s expectations, demonstrating robust STAT6 degradation and a favorable safety profile, thereby derisking the program, the company said in a press release.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 208
• Founded by Bruce Lee Booth and Nello Mainolfi in September 2015 
• Headquartered in Watertown, Massachusetts
• https://www.kymeratx.com

IPO: Aug 21, 20

 

 

 

 

Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. 

908 Devices (MASS) : 4-year performance

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets.

• Sector: Healthcare
• Industry: Medical Devices
• Full Time Employees: 230
• Incorporated in 2012 
• Headquartered in Boston, Massachusetts
• Website www.908devices.com

 

 

 

 

FuboTV (FUBO) : 5-year performance

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. 

• Founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 
• Headquartered in New York, NY
• IPO: October 8, 2020; This was technically an uplisting from OTC (where it traded as FUBO after a 2020 reverse merger with FaceBank Group) to the NYSE. 
• The initial offering was preceded by a merger between the streaming platform FuboTV and the AR/VR tech company FaceBank Group in April 2020. Furthermore, on October 29, 2025, a significant corporate restructuring was completed when The Walt Disney Company acquired a 70% stake in Fubo to merge it with Hulu's live TV service.

Ticker: FUBO

U.S.-listed IPOs, annual deal count and value

The value of new U.S. stock listings has only ticked up modestly from 2022, when rapidly rising interest rates and COVID-related distortions in some industries depressed IPO activity.

As of December 31, 2024. Source: Bloomberg Finance L.P.

Repare Therapeutics (RPTX) : 4-year performance

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. 

The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. 

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 129
• Incorporated in 2016 
• Headquartered in Montreal, Canada
• The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University.
• https://www.reparerx.com

On Thursday, Repare Therapeutics Inc (NASDAQ:RPTX) revealed data from its MYTHIC Phase 1 gynecologic expansion trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) for endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers.

As of the data cut-off date of November 14, 51 evaluable patients were enrolled in the gynecologic cancer expansion cohort of the MYTHIC trial.

Across all tumor types treated at the optimized RP2D (n=67), Lunre+Camo therapy showed a favorable and differentiated tolerability profile compared to current and emerging therapies.

The most common adverse event was anemia (26.9%, Grade 3).

Vertex (VERX) : 4-year performance

Vertex, Inc. engages in the provision of tax compliance software solutions.

• Sector: Technology
• Industry: Software - Application
• Full Time Employees: 1,500
• Founded in 1978 
• Headquartered in King of Prussia, Pennsylvania.
• https://www.vertexinc.com

Ticker:  VERX

Allegro MicroSystems (ALGM) : 4-year performance

Allegro MicroSystems, Inc. designs, develops, manufactures, and markets sensor integrated circuits (ICs) and application-specific analog power ICs for motion control and energy-efficient systems.

• Sector(s): Technology
• Industry: Semiconductors
• Full Time Employees: 4,593
• Founded in 1990 
• Headquartered in Manchester, New Hampshire
• https://www.allegromicro.com/en

Priced 25,000,000 shares of its common stock at $14.00 per share.

Ticker: ALGM

Compass Pathways (CMPS) : 4-year performance

Compass Pathways plc is a biotechnology company that focuses on mental health in the United Kingdom and the United States. 

• Sector: Healthcare
• Industry: Medical Care Facilities
• Full Time Employees: 166
• Founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 
• Headquartered in London, the United Kingdom
• https://compasspathways.com

IPO: September 18, 2020

 

 

Virios Therapeutics (VIRI) began trading on the Nasdaq on Thur 17 Dec 20

• Sector(s): Healthcare
• Industry: Biotechnology
• Full Time Employees: 3
• http://www.virios.com

 

Virios Therapeutics is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia ("FM"). Overactive immune response related to activation of tissue resident Herpes Simplex Virus-1 ("HSV-1") has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease ("IBS"), chronic fatigue syndrome and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease. While not completely understood, there is general agreement in the medical community that activation of HSV-1 is triggered by some form of environmental and/or health stressor. Our lead development candidate ("IMC-1"), is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination antiviral therapy designed to synergistically suppress HSV-1 activation and replication, with the end goal of reducing viral mediated disease burden.

Orphazyme (ORPH) : topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS)

• Pivotal trial did not meet primary and secondary endpoints evaluating impact on function and survival
• Orphazyme remains focused on commercial readiness and potential U.S. approval of arimoclomol for Niemann-Pick disease type C (NPC) in June 
• Sept 29, 20: Orphazyme, a Danish late-stage biotech developing protein therapies for rare neurodegenerative diseases, raised $84 million by offering 7.6 million ADS equivalents at $11, below the as-converted last close of its shares on the Nasdaq Copenhagen (ORPHA). At pricing, the company raised -16% less in proceeds than anticipated.

Copenhagen – May 7, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today announced that the ORARIALS-01 pivotal trial of arimoclomol in amyotrophic lateral sclerosis (ALS) did not meet its primary and secondary endpoints to show benefit in people living with ALS. No important safety signals were reported in the trial. Topline data will be presented at the upcoming virtual European Network to Cure ALS (ENCALS) meeting, May 12-14, and complete data from the study will be published later this year.

“We are disheartened by these results, as we had hoped arimoclomol might represent a viable new approach against the formidable challenge of this devastating disease. We express our sincere thanks to the investigators, patients and families for their participation and collaboration in our program,” said Thomas Blaettler, MD, Chief Medical Officer, Orphazyme. “With over 18 months of evaluation, this trial represents one of the longest running clinical studies in this category. While unsuccessful, the data generated will contribute meaningfully to the scientific dialogue on this challenging disease. We will apply the invaluable insights from this and other studies to further our pipeline as we continue to pursue the full potential of the heat shock protein response.”

The randomized, placebo-controlled Phase 3 trial was conducted among 245 patients at 29 sites in 12 countries in North America and Europe. Participants were randomized (2:1 ratio) to receive either arimoclomol (248 mg three times daily)i or placebo for up to 76 weeks. The primary endpoint was to determine the efficacy of chronic treatment with arimoclomol compared to placebo in participants with ALS as assessed by the combined assessment of function and survival (CAFS). This endpoint was selected to illustrate the overall treatment effect based on survival and the change in the ALS Functional Rating Scale-Revised (ALSFRS-R) score. Secondary endpoints included survival, change in ALSFRS-R, and slow vital capacity (SVC).

About arimoclomol

Arimoclomol is an investigational drug candidate that amplifies the production of heat shock proteins (HSPs). HSPs can rescue defective misfolded proteins, clear protein aggregates, and improve the function of lysosomes. Arimoclomol is administered orally, and has now been studied in 10 phase 1, four phase 2 and three pivotal phase 2/3 trials. Arimoclomol is in clinical development for NPC and Gaucher disease. Arimoclomol has received orphan drug designation (ODD) for NPC in the US and EU. Arimoclomol has received fast-track designation (FTD) from the U.S. Food and Drug Administration (FDA) for NPC. In addition, arimoclomol has received breakthrough therapy designation (BTD) and rare-pediatric disease designation (RPDD) from the FDA for NPC. Arimoclomol is an investigational treatment and has not been approved by the FDA.

Skillz (SKLZ)

Skillz is a mobile gaming/esports platform where users can compete and game developers share revenue.

• Investors including Wellington, Fidelity, Franklin Templeton, and Neuberger Berman funds have committed to a $159 million PIPE with total commitments exceeding $250 million.
• High growth business with projected 2022 revenue of $555 million, a 57% CAGR from 2020
• Andrew Paradise, CEO & Founder of Skillz, and Casey Chafkin, CRO and Founder of Skillz, will continue to lead the company
• Existing Skillz stockholders and Flying Eagle sponsor agreed to 24-month lock-up

Flying Eagle Acquisition Corp. (NYSE: FEAC) is headed by Harry Sloan, a media executive who was formerly the CEO of MGM. Sloan was also behind Diamond Eagle Acquisition Corp., which took fantasy sports platform DraftKings public via SPAC in 2020.

First day of trading Dec 17, 2020:  Opened at $17.89, closed $22.73.

Sigilon Therapeutics (SGTX) began trading on the Nasdaq on Fri 4 Dec 20

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. 

• Sector(s): Healthcare
• Industry: Biotechnology
• Full Time Employees: 62
• Incorporated in 2015 
• Headquartered in Cambridge, Massachusetts
• https://sigilon.com

Luminar Technologies (LAZR) : 3-month performance

• Luminar Technologies Inc started trading as a public company on Thursday under the ticker symbol LAZR, marking the second Silicon Valley firm to go public while working to deliver a key sensor for self-driving cars.
• Luminar makes a lidar sensor, which helps gives vehicles a three-dimensional view of the road. It became public through a merger with Gores Metropoulos Inc, a special purpose acquisition company, or SPAC, a shell company that uses proceeds from an IPO to acquire a private company, typically within two years.

HF Enterprises (HFEN) began trading on the Nasdaq on Tue 24 Nov 20

• Changed name to Alset EHome International (AEI) Feb 4, 2021 
• https://www.hfenterp.com/

HF Enterprises (HFEN), a holding company with investments in real estate, tech, and healthcare, downsized and priced at the high end to raise $15 million at a $60 million market cap. The company is unprofitable and saw revenue plummet 71% in the 1H20. HF Enterprises finished down 13% on IPO day.